Immune-related effects in hypertension and target-organ damage

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 2, 2011, Pages 113-117

  Muller, Dominik N ^a,b   Kvakan, Heda ^b,c   Luft, Friedrich C ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b Experimental and Clinical Research Center   (Germany)

^c Helios Hospital Berlin Buch   (Germany)

Author keywords

hypertension; macrophages; T cells; target organ damage

Indexed keywords

ANGIOTENSIN II; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; DEOXYCORTICOSTERONE ACETATE; DEXAMETHASONE; ETANERCEPT; GAMMA INTERFERON; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRROLIDINE DITHIOCARBAMATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHRONIC DISEASE; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; HEART MUSCLE INJURY; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE ACTIVATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; SODIUM BALANCE; SYSTOLIC HYPERTENSION; TARGET ORGAN; TH1 CELL; TH17 CELL; TH2 CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PRESSURE; HUMANS; HYPERTENSION; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGES; MONOCYTES; NF-KAPPA B; T-LYMPHOCYTES;

EID: 79952041611     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283436f88     Document Type: Article

References (28)

1. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321:199-204. (Pubitemid 30459555)
2. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843. (Pubitemid 30165206)
3. NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477-1490.
4. The ACCORD Study Group, Cushman WC, Evans GW et al Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 362 1575-1585.
5. Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53:49-57.
6. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-2357. (Pubitemid 16136806)
7. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007; 117:1119-1127. (Pubitemid 46718396)
8. David M, Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-969.
9. Machnik A, Neuhofer W, Jantsch J, et al. Macrophages regulate salt-dependent volume and blood pressure by a VEGF-C dependent buffering mechanism. Nat Med 2009; 15:545-552.
10. Titze J, Machnik A. Sodium sensing in the interstitium and relationship to hypertension. Curr Opin Nephrol Hypertens 2010; 19:385-392.
11. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? Clin Invest 2001; 107:255-264. (Pubitemid 32157955)
12. Thome M, Weil R. Posttranslational modifications regulate distinct functions of CARMA1 and BCL10. Trends Immunol 2007; 28:281-288. (Pubitemid 46824086)
13. McAllister-Lucas LM, Jin X, Gu S, et al. The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem 2010; 285:25880-25884.
14. McAllister-Lucas LM, Ruland J, Siu K, et al. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci USA 2007; 104:139-144. (Pubitemid 46067998)
15. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3:894-899. (Pubitemid 27353450)
16. Vos IH, Govers R, Grone HJ, et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. Faseb J 2000; 14:815-822. (Pubitemid 30198580)
17. Muller DN, Dechend R, Mervaala EM, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000; 35:193-201. (Pubitemid 30054172)
18. Freund C, Schmidt-Ullrich R, Baurand A, et al. Requirement of nuclear factorkappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005; 111:2319-2325. (Pubitemid 40647067)
19. Henke N, Schmidt-Ullrich R, Dechend R, et al. Vascular endothelial cellspecific NF-kB suppression attenuates hypertension-induced renal damage. Circ Res 2007; 101:268-276. (Pubitemid 47344076)
20. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-2460. (Pubitemid 47529329)
21. Sriramula S, Haque M, Majid DAS, Francis J. Involvement of tumor necrosis factor-a in angiotensin ii-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008; 51:1345-1351. (Pubitemid 351555948)
22. Madhur MS, Lob HE, McCann LA, et al. Interleukin17 promotes angiotensin IIinduced hypertension and vascular dysfunction. Hypertension 2010; 55:500-507.
23. Seaberg EC, Muñ oz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from .1984. to 2003. AIDS 2005; 19:953-960. (Pubitemid 40834939)
24. Herrera J, Ferrebuz A, MacGregor EG, Rodŕguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006; 17 (suppl 3):S218-S225. (Pubitemid 44865252)
25. Hughson MD, Gobe GC, Hoy WE, et al. Associations of glomerular number and birth weight with clinicopathological features of African Americans and whites. Am J Kidney Dis 2008; 52:18-28. (Pubitemid 351853270)
26. Muller DN, Shagdarsuren E, Park JK, et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002; 161:1679-1693. (Pubitemid 35265527)
27. Crowley SD, Frey CW, Gould SK, et al. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 2008; 295:F515-F524.
28. Kvakan H, Kleinewietfeld M, Qadri F, et al. Regulatory T cells ameliorate Ang IIinduced cardiac damage. Circulation 2009; 119:2904-2912.